Nutrition in Gastrointestinal Tumors

NCT ID: NCT04476082

Last Updated: 2023-01-25

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

66 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-06-25

Study Completion Date

2022-12-06

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Malnutrition and loss of muscle mass frequently occur in patients undergoing chemotherapy and can negatively effect therapy outcome. Especially patients with cancer of the gastrointestinal tract are often affected by malnutrition. Therefore, this study aims to examine changes in nutritional status of patients with cancer of the gastrointestinal tract during chemotherapy. Findings of this study will help to improve nutritional treatment of patients undergoing chemotherapy.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Malnutrition and sarcopenia are common complications in patients with malignant diseases of the gastrointestinal tract. During chemotherapy there is a high risk of further impairment of nutritional status due to anorexia, nausea, emesis and other gastrointestinal conditions that adversely impact food assimilation or absorption. Findings on changes of nutritional status during chemotherapy are scarce but of paramount importance for adequate nutrition therapy. Therefore, this study aims to provide a detailed description of changes in nutritional status of patients with a malignant condition of the gastrointestinal tract during chemotherapy.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pancreatic Cancer Oesophageal Cancer Colon Cancer Liver Cancer Rectal Cancer Bile Duct Cancer GIST, Malignant Neuroendocrine Tumors Small Intestine Cancer Gastric Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Initial Diagnosis

Patients with initial diagnosis of a malignant condition of the gastrointestinal tract planned to receive cytostatic treatment.

No intervention - observational study only

Intervention Type OTHER

No intervention - observational study only

Ongoing Cytostatic Treatment

Patients with a malignant condition of the gastrointestinal tract already receiving cytostatic treatment.

No intervention - observational study only

Intervention Type OTHER

No intervention - observational study only

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

No intervention - observational study only

No intervention - observational study only

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with initial diagnosis of a malignant condition of the gastrointestinal tract planned to receive cytostatic treatment.
* ongoing cytostatic treatment of a known malignant condition of the gastrointestinal tract

Exclusion Criteria

* pregnancy
* history of any other malignant tumor disease
* inability to provide consent
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Medicine Greifswald

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ali A Aghdassi, Professor

Role: PRINCIPAL_INVESTIGATOR

University Medicine Greifswald

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University Medicine Greifswald

Greifswald, , Germany

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Germany

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

BB 071/20

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.